Because the proposed pathogenesis of CIDP is that of an immune-mediated condition, appropriate agents include intravenous immunoglobulin (IVIg), plasma exchange, prednisone, azathioprine, methotrexate, mycophenolate, cyclosporine, and cyclophosphamide. High-dose steroids or IVIg could be considered as the initial treatment in patients with CIDP.
Although plasma exchange has been shown to improve outcome in patients with CIDP, it is not always a feasible choice for some patients because it may not be readily available in rural areas. Moreover, both plasma exchange and IVIg are costly treatments. Still, plasma exchange may be particularly beneficial in patients with a relapsing course.
Learn more about medication in CIDP treatment.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jafar Kafaie. Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management - Medscape - Jun 24, 2021.
Comments